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Clinical studies have shown that Selank had an anxiolytic effect comparable to that
of classical benzodiazepine drugs, which can enhance the inhibitory effect of GABA
by allosteric modulation of GABAA receptors. These data suggest that the molecular
mechanism of the effect of Selank may also be related to its ability to affect the
performance of the GABAergic system. To test this hypothesis, we studied the changes
in expression of 84 genes involved in the functioning of the GABAergic system and in
the processes of neurotransmission in the culture of neuroblastoma IMR-32 cells using
qPCR method. As test substances, in addition to Selank, we selected the major GABAA
receptor ligand, GABA, the atypical antipsychotic, olanzapine, and combinations of these
compounds (Selank and GABA; Selank and olanzapine). We found no changes in the
mRNA levels of the genes studied under the effect of Selank. The combined effect of
GABA and Selank led to nearly complete suppression of changes in expression of genes
in which mRNA levels changed under the effect of GABA. When Selank was used in
conjunction with olanzapine, the expression alterations of more genes were observed
compared with olanzapine alone. The data obtained indicate that Selank has no direct
effect on the mRNA levels of the GABAergic system genes in neuroblastoma IMR-32
cells. At the same time, our results partially confirm the hypothesis that the peptide may
affect the interaction of GABA with GABAA receptors. Our data also suggest that Selank
may enhance the effect of olanzapine on the expression of the genes studied.
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INTRODUCTION
Drugs that are based on natural regulatory peptides are currently becoming more widely used.
Synthetic analogs of regulatory peptides typically contain only natural amino acids in their
structure, so that they practically do not have any toxic side effects. Drugs that are developed on the
basis of regulatory peptides can provide directional effects on certain human body systems and are
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already used for the treatment of a variety of human
diseases, such as cardiovascular disease (Gusev et al., 1997),
gastrointestinal disease (Ivanov Iu and Iasnetsov, 2000), viral
infections (Ershov et al., 2009; Andreeva et al., 2010), and various
pathologies of the nervous system (Gusev et al., 2005).
Selank is a synthetic analog of the natural immunopeptide
taftsin, belonging to a group of drugs of peptidic nature, and was
developed at the Institute of Molecular Genetics of the Russian
Academy of Sciences, in cooperation with the Zakusov Scientific
Research Institute of Pharmacology. This peptide consists of the
short fragment Thr-Lys-Pro-Arg of the heavy chain of the human
immunoglobulin G and the tripeptide Pro-Gly-Pro at the end of
the molecule, which provides metabolic stability and duration
of action of the drug (Ashmarin et al., 2005; Ashmarin, 2007).
Clinical trials of Selank have shown that this peptide can affect
both the immune and the nervous system (Czabak-Garbacz et al.,
2006; Semenova et al., 2008). It was shown that Selank had
a pronounced anxiolytic effect comparable to that of classical
benzodiazepine drugs (Seredenin et al., 1990, 1998). It is known
that the classical benzodiazepines act via gamma-aminobutyric
acid (GABA) type A receptors. They enhance the GABA effect by
allosteric modulation, which increases the frequency of opening
of channels for chlorine ions. The Selank action mechanism may
be related to its ability to affect the performance of the GABAergic
system.
Previously, it was shown that Selank causes a marked change
in the expression of genes involved in inflammatory processes in
the hippocampus and spleen of rodents (Kolomin et al., 2010,
2011, 2014). Our results have confirmed at the molecular level
that the clinical effects observed after the introduction of Selank
are related to its antiviral activity (Ershov et al., 2009; Andreeva
et al., 2010).
Recent studies have shown that amount of specifically bound
ligand ([3H]GABA) changes in the presence of Selank, and
Selank preliminary intranasal administration causes a change in
the number of GABA-specific binding sites but does not affect
receptor affinity (V’yunova et al., 2014). Based on these data,
the authors suggested that Selank can lead to a rapid change
in the GABAergic system state by binding to GABA receptors
and allosterically modulating the activity of GABAA receptor.
It is possible that the transcriptome changes that we previously
identified are implemented partially via modulation of activity
of GABAA receptors by Selank. Earlier, we also found a positive
correlation between the changes in the expression of genes
involved in neurotransmission in the frontal cortex of rats within
1 h after administration of Selank or GABA. Our results showed
that Selank caused a number of alterations in the expression of
genes involved in the functioning of the GABAergic system and
in the processes of neurotransmission (Volkova et al., 2016).
To test the hypothesis of a possible effect of Selank through
the regulation of the activity of GABAA receptors, we studied the
changes in expression of 84 genes involved in neurotransmission
in the IMR-32 cell line in response to Selank. The human
neuroblastoma cell line, IMR-32, was chosen for study because
these cells express functional GABAA receptors (Anderson et al.,
1993; Noble et al., 1993; Sapp and Yeh, 2000). To detect the
effects associated with the action on the GABAA receptor,
we also conducted analysis of the changes in gene expression
in response to GABA, a major GABAA receptor ligand, and
olanzapine, which is an atypical benzodiazepine that has the most
pronounced affinity for 5-HT2 receptors (Bymaster et al., 1996).
MATERIALS AND METHODS
Cells and Reagents
The human neuroblastoma cell line, IMR-32, was obtained from
the A.T.C.C. (LGC Standards Sp. z.o.o., Poland). The cells
were maintained in a humidified atmosphere containing 5%
CO2 and 95% humidified air at 37◦C in Dulbecco’s modified
Eagle’s medium (DMEM) with L-glutamine (PanEco, Russia)
supplemented with 10% fetal bovine serum (FBS) (PanEco), and
gentamicin (50 mkg/ml) (Veropharm, Russia).
Selank, GABA, and Olanzapine Treatment
IMR-32 cells were seeded into 6-well plates (Corning, The
Netherlands) at 1–2 million cells per well in 4 ml of cell culture
medium with Phenol Red per well, following incubation for 24 h
at 37◦C to allow the cells to adhere. After 24 h of incubation,
physiological solution (50 mkl), Selank (1 nmol per well), GABA
(1 nmol per well), olanzapine (1 nmol per well), a mixture of
GABA and Selank (1 nmol of GABA and 1 nmol of Selank
per well), or a mixture of Selank and olanzapine (1 nmol of
Selank and 1 nmol of olanzapine per well) were added into the
culture medium and the cells were incubated with the reagents
for 1 h. The specified dose of Selank was selected as an optimum
dose, that is used in studies of effects of peptides in cell cultures
(Dolotov et al., 2015). All procedures were performed twice. After
incubation with the reagents, the cells were washed with 1 ml
of the physiological solution and immediately lyzed with 0.5
ml of Trizol reagent (Invitrogen, Thermo Fisher Scientific Inc.)
per well. The lyzed cells were stored at −70◦C prior to further
procedures.
RNA Purification, Reverse Transcription,
and Quantitative Real-Time PCR (qPCR)
The lysates were incubated at −20◦C for 1 h, then at +4◦C
for 1 h prior to RNA purification. Chloroform (0.1 ml) was
added to each lysate. Tubes were shaken vigorously by hand
for 15 s and incubated at room temperature for 3 min. After
incubation, the samples were centrifuged at 12000 × g for 15
min at +4◦C. The aqueous phase was placed into a new tube
and the RNA isolation procedure was carried out using the
QIAamp R© RNA mini kit (Qiagen, Germany) according to the
manufacturer’s recommendations. RNA quality was monitored
using an Experion automated electrophoresis system (Bio-Rad
Laboratories). The RNA quality index was higher than 8.5 in
all samples. First-strand cDNAs were synthesized using the
RT2 First Strand Kit (Qiagen) according to the manufacturer’s
protocol. qPCR was performed using the Custom Human RT2
ProfilerTM PCR Array: CAPH11633C (Qiagen). Amplification
was carried out on the StepOnePlusTM Real-Time qPCR System
(Life Technologies, USA) using the RT2 SYBR Green Mastermix
(Qiagen, Germany). Thermal cycling was carried out as follows:
(1) 95◦C for 600 s, followed by (2) 40 cycles of 15 s at 95◦C
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and 60 s at 60◦C. All reactions were repeated three times for
the cDNAs from each experimental and control cells. The qPCR
study follows the MIQE guidelines.
Statistical Analysis
The threshold reaction cycle (Cq) values obtained for the
genes studied were normalized to the Cq-values of the four
reference genes: TFRC, TSPO, B2M, and UBC. Statistical data
analysis of the normalized Cq-values and identification of
significant differences between the levels of expression of the
genes studied in nerve cells in the human neuroblastoma
cell line IMR-32 after the incubation with the physiological
solution and in the cells after the incubation with the substances
studied was performed using the RT2 Profiler PCR Array Data
Analysis version 3.5 (http://pcrdataanalysis.sabiosciences.com/
pcr/arrayanalysis.php). Data analysis is based on the 11Cq
method with normalization of the raw data to reference genes.
Genes in which the mRNA level changed significantly (p ≤ 0.05)
1.5 times or more were taken into account in the analysis of the
changes in expression under the action of the test compounds.
A comparison of significant changes of gene expression after
the incubation with the substances studied was performed using
the Spearman’s rank correlation coefficient with Statistica v8.0
software. The gene set enrichment analysis (GSEA) of the
genes studied and visualization of functional relations between
proteins, encoded by these genes, were performed using Pathway
Studio version 11.2.5.9 (Elsevier, USA).
RESULTS
We studied the effects of Selank, GABA, olanzapine, as well as
combinations of these compounds (Selank and GABA; Selank
and olanzapine) on the changes of mRNA levels of the 84
genes involved in neurotransmission processes in nerve cells
in the human neuroblastoma cell line IMR-32. Preliminary
analysis showed that the values of threshold cycles (Cq) of 15
genes studied (BIRC3, CACNA1A, CX3CR1, DRD1, GABRA4,
GABRA6, GABRD, GABRP, GABRR1, HCRT, IL2, MMP7,
NPFFR2, SLC6A12, and PTGS2) were higher than 35, which
indicates the low representation of mRNA in cells examined.
Therefore, these genes were excluded from further analysis.
The results of the expression analysis of the effects of Selank,
GABA, olanzapine, and their combinations on the expression of
69 genes are shown in Table 1. After incubation of IMR-32 cells
with GABA, 14 genes changed their expression with the majority
of them (11) showing a decrease in the mRNA level. The mRNA
levels of three genes increased: GABRG2 increased 1.7 times, and
GABRA5 and GNAQ increased 1.6 times. Incubation of the cell
culture with olanzapine resulted in changes of expression of 25
genes: transcript levels of 21 genes were decreased. The decrease
in expression of three genes was especially pronounced in CSF2
(4.5 times), FOS (3 times), and JUNB (5.3 times). Four genes
(GABRA5, GABRG2, GNACQ, and SNCA) showed an increase
of expression of no more than 2-fold compared with the control
cells. It should be noted that there were no changes in the mRNA
levels of the genes studied under the effect of Selank in the
IMR-32 cells.
Statistically significant change in the expression of only one
gene, JUNB, whose mRNA level decreased 1.7 times, was shown
after incubation of the IMR-32 cells simultaneously with Selank
and GABA. At the same time, changes in the mRNA levels of
the greatest number of genes were shown after incubation of the
IMR-32 cells simultaneously with Selank and olanzapine when
compared with all compounds and their combinations studied.
Significant changes in the expression of 35 of 69 genes chosen
for the analysis were shown: 29 genes showed decreased mRNA
levels, and transcript levels of 10 of them (ADORA2A, CSF2,
CX3CL1, DRD3, FOS, GABBR1, JUNB, MMP10, NPFFR1, and
SLC32A1) decreased more than 3 times. The mRNA levels of six
genes (BIRC2, GABRA5, GABRG2, GNAQ, ODC1, and SNCA)
increased after the incubation of the IMR-32 cells with Selank and
olanzapine.
The cumulative analysis of all obtained statistically significant
data showed that after the incubation of IMR-32 neuroblastoma
cells with all the compounds and their combinations a
decrease in mRNA levels of most of the genes studied (31)
was observed; in contrast, mRNA levels of only six genes
(BIRC2, GABRA5, GABRG2, GNAQ, ODC1, and SNCA) were
increased.
It should also be noted that the most pronounced change in
expression was observed for two genes, CSF2 and JUNB, after
incubation of cells with the compounds studied. mRNA levels of
these genes decreased three times after incubation with GABA,
4.5 and 5.3 times after incubation with olanzapine, and 6.3 and
6.7 times after incubation with Selank and olanzapine. Moreover,
the JUNB gene was characterized by a significant 1.7-fold
decrease in expression after incubation of the cells with GABA
and Selank. This gene is the only one in which mRNA levels
changed significantly in the four variants of incubation of IMR-
32 cells with various compounds (namely, GABA; olanzapine;
Selank and GABA; Selank and olanzapine).
Another interesting feature is that despite the fact that no
statistically significant change in expression of the genes under
study was observed under the effect of Selank, the combined
effect of GABA and Selank led to nearly complete suppression of
changes in expression of genes in which mRNA levels changed
under the effect of GABA (Figure 1). When Selank was used
in conjunction with olanzapine, the expression alterations of
more genes were observed compared with olanzapine alone.
Furthermore, changes in mRNA levels becamemore pronounced
(Figure 2).
The correlation analysis was conducted for genes in which
the mRNA levels significantly changed under the effect of the
compounds studied. As a result, we discovered a very strong
positive correlation between gene expression changes under the
effect of GABA and those under the effect of olanzapine (r= 0.98,
p ≤ 0.05).
We also conducted the Gene Set Enrichment Analysis
(GSEA) of the genes which mRNA levels changed significantly
in neuroblastoma cells IMR-32 after incubation with the
mixture of Selank and olanzapine. The results are shown in
Table 2. This group of genes was chosen for the analysis
because the mixture of Selank and olanzapine caused changes
in expression of the largest number of the genes when
Frontiers in Pharmacology | www.frontiersin.org 3 February 2017 | Volume 8 | Article 89
Filatova et al. Selank Affects the Expression of the GABAergic Genes
T
A
B
L
E
1
|
T
h
e
re
la
ti
v
e
m
R
N
A
le
v
e
ls
o
f
g
e
n
e
s
in
v
o
lv
e
d
in
n
e
u
ro
tr
a
n
s
m
is
s
io
n
p
ro
c
e
s
s
e
s
in
n
e
u
ro
b
la
s
to
m
a
IM
R
-3
2
c
e
ll
c
u
lt
u
re
a
ft
e
r
in
c
u
b
a
ti
o
n
w
it
h
G
A
B
A
,
o
la
n
z
a
p
in
e
,
S
e
la
n
k
,
S
e
la
n
k
w
it
h
G
A
B
A
,
o
r
S
e
la
n
k
w
it
h
o
la
n
z
a
p
in
e
.
G
e
n
e
S
y
m
b
o
l
O
ffi
c
ia
l
fu
ll
n
a
m
e
G
A
B
A
O
la
n
z
a
p
in
e
S
e
la
n
k
S
e
la
n
k
+
G
A
B
A
S
e
la
n
k
+
O
la
n
z
a
p
in
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
A
B
A
T
4
-a
m
in
o
b
u
ty
ra
te
a
m
in
o
tr
a
n
sf
e
ra
se
−
1
.4
3
0
.0
4
2
−
1
.8
9
0
.0
0
1
−
1
.0
1
0
.9
4
1
−
1
.3
4
0
.0
1
7
−
1
.9
6
0
.0
0
2
A
D
C
Y
7
A
d
e
n
yl
a
te
c
yc
la
se
7
−
2
.0
0
0
.0
6
6
−
2
.3
0
0
.0
3
9
1
.0
0
0
.9
3
4
−
1
.4
6
0
.1
4
5
−
2
.8
4
0
.0
2
3
A
D
O
R
A
1
A
d
e
n
o
si
n
e
A
1
re
c
e
p
to
r
−
1
.2
8
0
.3
4
6
−
1
.5
0
0
.0
4
7
−
1
.0
6
0
.5
9
2
−
1
.2
0
0
.2
4
1
−
1
.7
7
0
.0
1
1
A
D
O
R
A
2
A
A
d
e
n
o
si
n
e
A
2
a
re
c
e
p
to
r
−
3
.8
2
0
.0
4
0
−
2
.9
4
0
.0
7
2
−
1
.4
6
0
.2
3
7
−
2
.7
1
0
.0
5
9
−
3
.8
8
0
.0
3
2
A
L
D
H
5
A
1
A
ld
e
h
yd
e
d
e
h
yd
ro
g
e
n
a
se
5
fa
m
ily
,
m
e
m
b
e
r
A
1
−
1
.2
0
0
.2
5
1
−
1
.5
1
0
.0
0
8
−
1
.0
2
0
.7
6
1
−
1
.1
5
0
.1
3
6
−
1
.6
5
0
.0
0
5
B
C
L
2
B
-c
e
ll
C
L
L
/l
ym
p
h
o
m
a
2
−
1
.0
4
0
.6
7
0
−
1
.3
3
0
.0
9
9
−
1
.0
4
0
.7
0
1
−
1
.1
8
0
.2
0
9
−
1
.3
0
0
.1
1
6
B
C
L
2
L
1
B
C
L
2
-l
ik
e
1
−
1
.7
5
0
.0
5
0
−
2
.2
2
0
.0
0
5
−
1
.1
0
0
.3
6
2
−
1
.2
5
0
.0
9
6
−
2
.6
2
0
.0
0
2
B
D
N
F
B
ra
in
-d
e
riv
e
d
n
e
u
ro
tr
o
p
h
ic
fa
c
to
r
1
.0
6
0
.5
4
7
1
.0
6
0
.3
5
2
1
.0
8
0
.3
4
9
1
.0
7
0
.4
4
0
1
.1
5
0
.1
2
6
B
IR
C
2
B
a
c
u
lo
vi
ra
lI
A
P
re
p
e
a
t
c
o
n
ta
in
in
g
2
1
.3
5
0
.0
3
9
1
.4
2
0
.0
1
1
1
.0
2
0
.7
7
9
1
.1
6
0
.1
3
8
1
.5
7
0
.0
0
4
C
A
C
N
A
1
B
C
a
lc
iu
m
c
h
a
n
n
e
l,
vo
lta
g
e
-d
e
p
e
n
d
e
n
t,
N
ty
p
e
,
a
lp
h
a
1
B
su
b
u
n
it
−
1
.7
1
0
.0
6
5
−
2
.1
8
0
.0
4
1
−
1
.2
5
0
.3
3
8
−
1
.5
6
0
.1
0
3
−
2
.7
5
0
.0
1
9
C
C
N
D
1
C
yc
lin
D
1
−
1
.0
1
0
.9
5
4
−
1
.1
7
0
.0
6
7
−
1
.0
4
0
.5
6
0
−
1
.0
2
0
.6
5
1
−
1
.2
7
0
.1
0
6
C
S
F
2
C
o
lo
n
y
st
im
u
la
tin
g
fa
c
to
r
2
(g
ra
n
u
lo
c
yt
e
-m
a
c
ro
p
h
a
g
e
)
−
3
.0
7
0
.0
0
5
−
4
.4
8
0
.0
1
0
1
.1
1
0
.6
1
7
−
1
.4
3
0
.3
9
2
−
6
.2
1
0
.0
0
3
C
X
3
C
L
1
C
h
e
m
o
ki
n
e
(C
-X
3
-C
m
o
tif
)
lig
a
n
d
1
−
2
.3
1
0
.0
0
4
−
2
.7
0
0
.0
2
6
1
.0
6
0
.7
1
2
−
1
.2
9
0
.2
8
6
−
3
.7
4
0
.0
0
4
D
R
D
2
D
o
p
a
m
in
e
re
c
e
p
to
r
D
2
−
1
.4
6
0
.1
0
2
−
1
.6
5
0
.0
4
2
−
1
.0
5
0
.6
5
0
−
1
.1
8
0
.2
2
8
−
1
.9
2
0
.0
1
1
D
R
D
3
D
o
p
a
m
in
e
re
c
e
p
to
r
D
3
−
1
.5
6
0
.0
2
6
−
2
.3
5
0
.1
2
5
1
.2
3
0
.3
0
1
−
1
.3
4
0
.3
8
2
−
3
.0
2
0
.0
3
0
D
R
D
4
D
o
p
a
m
in
e
re
c
e
p
to
r
D
4
−
1
.7
0
0
.1
1
5
−
1
.6
9
0
.1
3
9
−
1
.1
9
0
.4
8
9
−
1
.3
0
0
.3
2
3
−
2
.1
5
0
.0
5
6
D
R
D
5
D
o
p
a
m
in
e
re
c
e
p
to
r
D
5
−
1
.0
7
0
.7
2
3
−
1
.4
4
0
.4
5
7
1
.2
5
0
.7
0
5
1
.1
8
0
.7
8
3
−
1
.8
1
0
.4
2
7
E
G
R
1
E
a
rly
g
ro
w
th
re
sp
o
n
se
1
−
1
.2
8
0
.2
4
0
−
1
.7
0
0
.1
1
2
−
1
.1
4
0
.5
9
3
−
1
.1
7
0
.5
1
7
−
1
.8
9
0
.0
5
9
F
N
1
F
ib
ro
n
e
c
tin
1
−
1
.5
9
0
.0
0
9
−
2
.0
6
0
.0
0
1
1
.0
1
0
.7
9
2
−
1
.2
8
0
.0
2
9
−
2
.2
3
0
.0
0
0
3
F
O
S
F
B
J
m
u
rin
e
o
st
e
o
sa
rc
o
m
a
vi
ra
lo
n
c
o
g
e
n
e
h
o
m
o
lo
g
−
1
.7
6
0
.0
8
4
−
3
.0
6
0
.0
0
1
−
1
.2
1
0
.2
9
3
−
1
.2
9
0
.0
6
1
−
3
.6
3
0
.0
0
2
G
A
B
B
R
1
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
B
re
c
e
p
to
r,
1
−
2
.1
1
0
.1
2
1
−
2
.3
8
0
.0
9
7
−
1
.0
1
0
.8
2
0
−
1
.3
4
0
.3
2
0
−
3
.1
1
0
.0
4
4
G
A
B
B
R
2
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
B
re
c
e
p
to
r,
2
−
1
.1
3
0
.5
3
4
−
1
.1
1
0
.6
2
0
1
.0
7
0
.7
7
1
1
.0
6
0
.7
4
5
−
1
.2
5
0
.3
5
7
G
A
B
R
A
1
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
a
lp
h
a
1
−
1
.3
6
0
.1
0
6
−
1
.5
4
0
.0
2
1
−
1
.1
4
0
.3
1
8
−
1
.1
3
0
.3
4
0
−
1
.3
5
0
.0
8
6
G
A
B
R
A
2
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
a
lp
h
a
2
1
.3
3
0
.0
7
6
1
.3
5
0
.0
2
2
−
1
.0
6
0
.4
7
7
1
.2
4
0
.0
3
9
1
.3
3
0
.0
3
9
G
A
B
R
A
3
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
a
lp
h
a
3
1
.1
6
0
.0
8
3
1
.0
9
0
.4
3
6
1
.0
3
0
.7
8
2
1
.1
1
0
.2
4
3
−
1
.0
0
0
.9
8
1
G
A
B
R
A
5
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
a
lp
h
a
5
1
.6
0
0
.0
2
6
1
.6
2
0
.0
0
9
1
.0
5
0
.6
4
1
1
.2
5
0
.0
5
9
1
.8
6
0
.0
0
5
G
A
B
R
B
1
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
b
e
ta
1
−
1
.2
8
0
.4
8
5
−
1
.5
6
0
.2
1
7
1
.1
2
0
.7
5
9
−
1
.0
0
0
.9
3
2
−
1
.5
8
0
.3
0
3
G
A
B
R
B
2
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
b
e
ta
2
1
.3
2
0
.0
8
2
1
.2
4
0
.1
4
8
−
1
.0
5
0
.9
4
5
1
.1
1
0
.5
9
5
1
.2
9
0
.1
0
4
G
A
B
R
B
3
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
b
e
ta
3
1
.3
2
0
.0
0
1
1
.0
9
0
.0
6
0
1
.0
4
0
.1
9
1
1
.0
7
0
.0
1
1
1
.1
2
0
.0
0
2
G
A
B
R
E
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
e
p
si
lo
n
−
1
.6
3
0
.1
8
5
−
1
.5
3
0
.3
5
4
1
.0
8
0
.8
0
0
1
.1
0
0
.8
8
9
−
1
.7
9
0
.1
3
7
G
A
B
R
G
1
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
g
a
m
m
a
1
1
.3
7
0
.0
6
9
1
.3
8
0
.0
6
5
1
.0
1
0
.7
6
7
1
.1
0
0
.5
4
1
1
.2
4
0
.2
7
0
(C
o
n
ti
n
u
e
d
)
Frontiers in Pharmacology | www.frontiersin.org 4 February 2017 | Volume 8 | Article 89
Filatova et al. Selank Affects the Expression of the GABAergic Genes
T
A
B
L
E
1
|
C
o
n
ti
n
u
e
d
G
e
n
e
S
y
m
b
o
l
O
ffi
c
ia
l
fu
ll
n
a
m
e
G
A
B
A
O
la
n
z
a
p
in
e
S
e
la
n
k
S
e
la
n
k
+
G
A
B
A
S
e
la
n
k
+
O
la
n
z
a
p
in
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
G
A
B
R
G
2
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
g
a
m
m
a
2
1
.6
5
0
.0
1
8
1
.7
4
0
.0
1
2
1
.3
8
0
.2
1
6
1
.4
7
0
.0
4
5
1
.7
4
0
.0
0
7
G
A
B
R
G
3
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
A
re
c
e
p
to
r,
g
a
m
m
a
3
1
.1
9
0
.1
4
9
1
.0
3
0
.8
3
8
1
.3
2
0
.2
2
7
1
.0
9
0
.4
7
6
−
1
.0
5
0
.6
0
8
G
A
B
R
Q
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
re
c
e
p
to
r,
th
e
ta
−
1
.6
2
0
.0
3
7
−
1
.9
2
0
.1
0
5
−
1
.0
8
0
.6
1
3
−
1
.4
5
0
.1
9
4
−
2
.6
2
0
.0
3
7
G
A
B
R
R
2
G
a
m
m
a
-a
m
in
o
b
u
ty
ric
a
c
id
(G
A
B
A
)
re
c
e
p
to
r,
rh
o
2
−
2
.0
3
0
.0
6
3
−
2
.4
7
0
.0
4
3
1
.0
1
0
.9
0
5
−
1
.5
0
0
.2
0
4
−
2
.7
8
0
.0
3
7
G
A
D
1
G
lu
ta
m
a
te
d
e
c
a
rb
o
xy
la
se
1
(b
ra
in
,
6
7
kD
a
)
−
1
.0
7
0
.6
2
2
−
1
.3
6
0
.4
6
8
1
.2
4
0
.7
8
5
1
.1
5
0
.8
6
0
−
2
.0
6
0
.2
4
9
G
L
S
G
lu
ta
m
in
a
se
1
.2
0
0
.0
4
3
1
.1
6
0
.0
3
9
1
.0
1
0
.8
5
7
1
.1
1
0
.0
1
9
1
.2
4
0
.0
0
3
G
L
U
L
G
lu
ta
m
a
te
-a
m
m
o
n
ia
lig
a
se
−
1
.0
1
0
.7
9
8
−
1
.1
4
0
.0
0
1
1
.0
2
0
.5
6
4
1
.0
2
0
.5
9
4
−
1
.1
7
0
.0
0
2
G
N
A
I1
G
u
a
n
in
e
n
u
c
le
o
tid
e
b
in
d
in
g
p
ro
te
in
(G
p
ro
te
in
),
a
lp
h
a
in
h
ib
iti
n
g
a
c
tiv
ity
p
o
ly
p
e
p
tid
e
1
1
.2
2
0
.0
6
4
1
.2
3
0
.0
6
2
1
.0
5
0
.5
8
7
1
.1
8
0
.0
6
7
1
.3
4
0
.0
0
8
G
N
A
Q
G
u
a
n
in
e
n
u
c
le
o
tid
e
b
in
d
in
g
p
ro
te
in
(G
p
ro
te
in
),
q
p
o
ly
p
e
p
tid
e
1
.5
7
0
.0
3
9
1
.6
9
0
.0
1
4
1
.0
7
0
.5
0
4
1
.2
4
0
.0
5
5
1
.8
7
0
.0
0
1
G
P
H
N
G
e
p
h
yr
in
1
.4
1
0
.0
0
6
1
.2
5
0
.0
2
2
1
.1
1
0
.1
9
8
1
.2
9
0
.0
0
8
1
.3
4
0
.0
0
5
G
P
R
8
5
G
p
ro
te
in
-c
o
u
p
le
d
re
c
e
p
to
r
8
5
−
1
.1
5
0
.2
1
8
−
1
.4
3
0
.0
1
5
−
1
.2
4
0
.0
7
3
−
1
.1
5
0
.0
5
6
−
1
.5
8
0
.0
0
4
H
C
R
T
R
2
H
yp
o
c
re
tin
(o
re
xi
n
)
re
c
e
p
to
r
2
−
1
.0
2
0
.8
2
6
−
1
.1
2
0
.8
3
5
1
.3
0
0
.5
5
5
1
.0
5
0
.9
7
8
1
.0
1
0
.8
2
2
H
T
R
1
B
5
-h
yd
ro
xy
tr
yp
ta
m
in
e
(s
e
ro
to
n
in
)
re
c
e
p
to
r
1
B
−
2
.3
2
0
.1
5
3
−
1
.9
7
0
.2
1
4
1
.0
6
0
.9
7
1
−
1
.5
7
0
.2
9
6
−
2
.2
8
0
.1
4
6
H
T
R
2
A
5
-h
yd
ro
xy
tr
yp
ta
m
in
e
(s
e
ro
to
n
in
)
re
c
e
p
to
r
2
A
−
1
.5
9
0
.0
5
4
−
2
.2
5
0
.0
4
5
−
1
.3
8
0
.6
8
1
−
1
.2
3
0
.7
0
9
−
2
.5
5
0
.0
5
1
H
T
R
3
A
5
-h
yd
ro
xy
tr
yp
ta
m
in
e
(s
e
ro
to
n
in
)
re
c
e
p
to
r
3
A
−
1
.9
0
0
.0
1
2
−
2
.2
5
0
.0
0
7
−
1
.1
5
0
.5
6
8
−
1
.4
9
0
.0
7
3
−
2
.8
3
0
.0
0
1
H
T
R
3
B
5
-h
yd
ro
xy
tr
yp
ta
m
in
e
(s
e
ro
to
n
in
)
re
c
e
p
to
r
3
B
−
1
.0
6
0
.7
7
1
−
1
.2
6
0
.5
6
3
1
.2
1
0
.7
8
5
1
.3
2
0
.6
3
6
−
1
.4
8
0
.5
5
1
IC
A
M
1
In
te
rc
e
llu
la
r
a
d
h
e
si
o
n
m
o
le
c
u
le
1
−
1
.4
5
0
.1
3
9
−
2
.3
0
0
.0
5
4
1
.0
5
0
.7
9
6
−
1
.1
1
0
.8
9
2
−
2
.6
7
0
.0
1
5
J
U
N
Ju
n
p
ro
to
-o
n
c
o
g
e
n
e
−
1
.4
7
0
.1
3
0
−
2
.0
1
0
.0
0
3
−
1
.2
0
0
.0
7
2
−
1
.3
4
0
.0
3
5
−
2
.3
7
0
.0
0
1
J
U
N
B
Ju
n
B
p
ro
to
-o
n
c
o
g
e
n
e
−
3
.1
4
0
.0
4
2
−
5
.1
9
0
.0
0
2
−
1
.2
3
0
.2
5
7
−
1
.7
1
0
.0
3
4
−
6
.5
7
0
.0
0
2
M
C
H
R
1
M
e
la
n
in
-c
o
n
c
e
n
tr
a
tin
g
h
o
rm
o
n
e
re
c
e
p
to
r
1
−
1
.2
7
0
.1
4
8
−
1
.5
8
0
.0
1
1
1
.0
5
0
.6
8
9
−
1
.3
7
0
.0
0
4
−
1
.8
4
0
.0
0
1
M
M
P
1
0
M
a
tr
ix
m
e
ta
llo
p
e
p
tid
a
se
1
0
(s
tr
o
m
e
ly
si
n
2
)
−
2
.2
5
0
.0
0
2
−
2
.7
9
0
.0
1
8
−
1
.3
4
0
.1
7
9
−
1
.5
3
0
.3
2
8
−
3
.5
0
0
.0
0
6
M
Y
C
V
-m
yc
m
ye
lo
c
yt
o
m
a
to
si
s
vi
ra
lo
n
c
o
g
e
n
e
h
o
m
o
lo
g
(a
vi
a
n
)
−
1
.2
1
0
.1
0
4
−
1
.4
9
0
.0
0
8
−
1
.0
8
0
.5
6
3
−
1
.2
5
0
.4
4
0
−
1
.1
7
0
.2
3
5
N
O
S
2
N
itr
ic
o
xi
d
e
sy
n
th
a
se
2
,
in
d
u
c
ib
le
−
1
.0
9
0
.8
5
9
−
1
.3
6
0
.1
6
0
1
.1
5
0
.4
6
8
1
.0
8
0
.7
2
4
−
1
.6
0
0
.0
5
6
N
P
F
F
R
1
N
e
u
ro
p
e
p
tid
e
F
F
re
c
e
p
to
r
1
−
2
.1
1
0
.0
4
4
−
2
.2
5
0
.0
7
2
1
.0
7
0
.8
3
2
−
1
.3
5
0
.3
5
7
−
3
.7
9
0
.0
2
0
N
S
F
N
-e
th
yl
m
a
le
im
id
e
-s
e
n
si
tiv
e
fa
c
to
r
1
.1
3
0
.0
0
0
4
−
1
.0
3
0
.1
5
5
1
.0
2
0
.1
9
0
1
.0
2
0
.1
9
0
1
.0
0
0
.6
8
9
O
D
C
1
O
rn
ith
in
e
d
e
c
a
rb
o
xy
la
se
1
1
.3
4
0
.0
2
7
1
.3
4
0
.0
2
7
1
.1
6
0
.0
8
3
1
.2
2
0
.0
2
3
1
.5
2
0
.0
0
7
P
2
R
X
7
P
u
rin
e
rg
ic
re
c
e
p
to
r
P
2
X
,
lig
a
n
d
-g
a
te
d
io
n
c
h
a
n
n
e
l,
7
1
.4
1
0
.5
5
0
1
.1
1
0
.9
7
2
1
.5
4
0
.4
0
5
1
.4
9
0
.4
5
1
−
1
.0
2
0
.7
3
6
P
R
K
C
A
P
ro
te
in
ki
n
a
se
C
,
a
lp
h
a
−
1
.2
9
0
.0
1
5
−
1
.5
7
0
.0
0
0
5
−
1
.0
1
0
.8
5
3
−
1
.1
7
0
.0
6
8
−
1
.7
0
0
.0
0
0
3
P
R
K
C
E
P
ro
te
in
ki
n
a
se
C
,
e
p
si
lo
n
−
1
.1
2
0
.4
4
6
−
1
.2
6
0
.0
2
8
1
.0
8
0
.2
5
2
−
1
.0
3
0
.7
6
6
−
1
.5
1
0
.0
0
3
P
R
L
H
R
P
ro
la
c
tin
re
le
a
si
n
g
h
o
rm
o
n
e
re
c
e
p
to
r
−
1
.8
4
0
.1
6
8
−
2
.1
8
0
.1
1
4
1
.2
3
0
.5
8
4
−
1
.0
7
0
.9
4
1
−
2
.7
3
0
.1
0
2
S
L
C
1
A
3
S
o
lu
te
c
a
rr
ie
r
fa
m
ily
1
(g
lia
lh
ig
h
a
ffi
n
ity
g
lu
ta
m
a
te
tr
a
n
sp
o
rt
e
r)
,
m
e
m
b
e
r
3
−
1
.1
6
0
.4
5
3
−
1
.3
0
0
.3
0
0
1
.0
9
0
.8
0
9
−
1
.1
7
0
.4
3
3
−
1
.4
8
0
.1
6
1
(C
o
n
ti
n
u
e
d
)
Frontiers in Pharmacology | www.frontiersin.org 5 February 2017 | Volume 8 | Article 89
Filatova et al. Selank Affects the Expression of the GABAergic Genes
T
A
B
L
E
1
|
C
o
n
ti
n
u
e
d
G
e
n
e
S
y
m
b
o
l
O
ffi
c
ia
l
fu
ll
n
a
m
e
G
A
B
A
O
la
n
z
a
p
in
e
S
e
la
n
k
S
e
la
n
k
+
G
A
B
A
S
e
la
n
k
+
O
la
n
z
a
p
in
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
F
o
ld
p
-v
a
lu
e
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
R
e
g
u
la
ti
o
n
S
L
C
3
2
A
1
S
o
lu
te
c
a
rr
ie
r
fa
m
ily
3
2
(G
A
B
A
ve
si
c
u
la
r
tr
a
n
sp
o
rt
e
r)
,
m
e
m
b
e
r
1
−
1
.7
3
0
.0
5
0
−
2
.3
2
0
.0
7
5
1
.0
2
0
.8
3
8
−
1
.3
3
0
.4
1
6
−
4
.0
1
0
.0
1
0
S
L
C
3
8
A
1
S
o
lu
te
c
a
rr
ie
r
fa
m
ily
3
8
,
m
e
m
b
e
r
1
1
.2
0
0
.0
8
7
1
.1
9
0
.0
1
4
1
.0
0
0
.9
6
6
1
.0
5
0
.2
5
3
1
.2
4
0
.0
1
3
S
L
C
6
A
1
S
o
lu
te
c
a
rr
ie
r
fa
m
ily
6
(n
e
u
ro
tr
a
n
sm
itt
e
r
tr
a
n
sp
o
rt
e
r,
G
A
B
A
),
m
e
m
b
e
r
1
−
1
.4
2
0
.3
0
2
−
1
.8
4
0
.1
3
4
1
.1
9
0
.5
7
3
1
.0
0
0
.8
8
8
−
2
.3
0
0
.1
1
4
S
L
C
6
A
1
1
S
o
lu
te
c
a
rr
ie
r
fa
m
ily
6
(n
e
u
ro
tr
a
n
sm
itt
e
r
tr
a
n
sp
o
rt
e
r,
G
A
B
A
),
m
e
m
b
e
r
1
1
−
1
.6
7
0
.0
7
2
−
1
.8
8
0
.0
4
4
−
1
.0
7
0
.6
7
4
−
1
.3
8
0
.1
7
8
−
2
.1
5
0
.0
3
1
S
L
C
6
A
1
3
S
o
lu
te
c
a
rr
ie
r
fa
m
ily
6
(n
e
u
ro
tr
a
n
sm
itt
e
r
tr
a
n
sp
o
rt
e
r,
G
A
B
A
),
m
e
m
b
e
r
1
3
−
1
.1
5
0
.5
6
1
−
1
.3
7
0
.2
6
7
1
.3
0
0
.3
4
3
1
.1
3
0
.7
1
7
−
1
.5
6
0
.1
4
3
S
L
C
8
A
3
S
o
lu
te
c
a
rr
ie
r
fa
m
ily
8
(s
o
d
iu
m
/c
a
lc
iu
m
e
xc
h
a
n
g
e
r)
,
m
e
m
b
e
r
3
−
1
.2
0
0
.3
7
9
−
1
.5
2
0
.0
9
5
−
1
.1
0
0
.5
1
4
−
1
.1
1
0
.5
1
4
−
1
.8
3
0
.0
3
9
S
N
C
A
S
yn
u
c
le
in
,
a
lp
h
a
(n
o
n
A
4
c
o
m
p
o
n
e
n
t
o
f
a
m
yl
o
id
p
re
c
u
rs
o
r)
1
.4
7
0
.1
1
3
1
.7
1
0
.0
2
6
−
1
.0
9
0
.6
2
4
1
.1
7
0
.3
5
8
1
.8
4
0
.0
1
3
T
h
e
d
a
ta
in
b
o
ld
d
e
n
o
te
c
h
a
n
g
e
s
in
th
e
e
xp
re
s
s
io
n
b
y
1
.5
ti
m
e
s
o
r
m
o
re
,
w
it
h
a
s
ig
n
ifi
c
a
n
c
e
le
ve
l(
p
<
0
.0
5
).
T
h
e
re
d
c
o
lo
r
d
e
n
o
te
s
th
e
in
c
re
a
s
e
in
e
xp
re
s
s
io
n
o
f
g
e
n
e
s
;
th
e
b
lu
e
c
o
lo
r
d
e
n
o
te
s
th
e
d
e
c
re
a
s
e
in
e
xp
re
s
s
io
n
o
f
g
e
n
e
s
.
FIGURE 1 | The relative change in gene expression in neuroblastoma
cells IMR-32 after incubation with GABA and after incubation with
Selank and GABA. The figure shows only statistically significant results
(p ≤ 0.05). mRNA levels of genes in the control group were taken as 1.
compared with other substances studied. Moreover, almost
all of the genes, which expression was significantly affected
by olanzapine, were also in the group that was chosen for
GSEA.
DISCUSSION
Clinical studies have shown that Selank is highly effective in
the prevention and treatment of generalized anxiety disorder
and neurasthenia, as well as stress and anxiety. This effect of
the peptide is similar to that of classical benzodiazepine drugs
(Seredenin et al., 1990, 1998), which can enhance the inhibitory
effect of GABA by allosteric modulation of GABAA receptors.
This suggests that the molecular mechanism of the effect of
Selank may also be related to its ability to affect the GABA
receptors.
We assessed changes in the expression of 84 genes involved in
the functioning of the GABAergic system and in the processes
of neurotransmission in the culture of neuroblastoma IMR-32
cells. It was shown that this cell line expresses predominantly
functional GABAA receptors (Anderson et al., 1993; Noble et al.,
1993; Sapp and Yeh, 2000), and therefore was chosen for our
study. As test substances, in addition to Selank, we selected the
primary ligand of the GABAA receptor, GABA, and the atypical
antipsychotic, olanzapine, which has an affinity for the serotonin
5-HT2-receptor.
The absence of any changes in the mRNA levels of genes
studied after the incubation of the cells with Selank suggests that
Selank is not able to directly affect the activity of the GABAergic
system in IMR-32 cell culture. We previously demonstrated
that Selank changes the expression of significant amounts of
genes involved in neurotransmission processes in neuronal cells
in the frontal cortex of rats (Volkova et al., 2016). Similar
changes in the expression of these genes were also observed
upon administration of GABA. The data obtained earlier indicate
that Selank is able to allosterically modulate the work of the
GABAergic system. It is also known that the interaction of some
allosteric modulators with the GABA receptor is determined by
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FIGURE 2 | The relative change in gene expression in neuroblastoma cells IMR-32 after incubation with olanzapine and after incubation with
olanzapine and Selank. The figure shows only statistically significant results (p ≤ 0.05). mRNA levels of genes in the control group were taken as 1.
TABLE 2 | Biological processes that were revealed by GSEA of the genes which mRNA levels changed significantly in neuroblastoma cells IMR-32 after
incubation with the mixture of Selank and olanzapine.
Name of biological process GO ID Number of Overlap Overlapping entities p-value
entities
Gamma-aminobutyric acid signaling
pathway
7214 29 7 GABRR2; GABRA2; GABBR1; GABRA5; GABRB3; GABRG2; GABRQ 1.15E-13
Transmembrane transport 55085 805 13 SLC8A3; GABRB3; ADCY7; GABRA5; CACNA1B; SLC6A11; SLC32A1;
SLC38A1; GABRR2; GABRQ; GABRA2; HTR3A; GABRG2
3.22E-09
Neurotransmitter secretion 7269 72 6 ALDH5A1; CACNA1B; SLC6A11; SLC32A1; ABAT; GLS 6.27E-09
Ion transport 6811 627 11 GABRA5; CACNA1B; SLC32A1; SLC38A1; GABRR2; GABRQ; SLC8A3;
GABRA2; GABRB3; HTR3A; GABRG2
2.86E-08
Signal transduction 0007165;
0023033
1843 17 ADORA1; ADCY7; GNAQ; GABRB3; GNAI1; DRD3; DRD2; GABRA5;
GABRR2; GABRQ; MCHR1; GPR85; PRKCE; ADORA2A; GABBR1; PRKCA;
GABRG2
3.08E-08
Response to organic cyclic
compound
14070 253 8 JUNB; BIRC2; ICAM1; BCL2L1; CACNA1B; FOS; JUN; PRKCA 3.31E-08
Response to drug 0042493;
0017035
509 10 DRD3; DRD2; JUNB; ICAM1; SLC6A11; FOS; JUN; ABAT; SNCA; ADORA2A 4.73E-08
Ion transmembrane transport 34220 291 7 GABRA2; GABRA5; GABRB3; GABRR2; GABRQ; HTR3A; GABRG2 1.63E-06
the subunit composition of this receptor (Sieghart, 1995; Zezula
et al., 1996; Rudolph and Knoflach, 2011). Currently, the subunit
composition of GABAA receptors present in neuroblastoma
IMR-32 cell culture is not precisely defined. mRNAs of some
genes that code α1, α3, α4, β1, β3, γ2, and δ subunits of GABAA
receptors were discovered in this cell culture (Sapp and Yeh,
2000). However, presently, only the expression of α3, β1, β3,
and γ2 subunits has been confirmed at the protein level by
Western blot hybridization and electrophysiological methods
(Noble et al., 1993; Sapp and Yeh, 2000). These data indicate
that the variants of GABAA-receptors, the subunit composition
of which is very limited, function in the IMR-32 cell line.
Thus, it can be assumed that Selank has no direct effect on
GABAA receptors, presented in the IMR-32 cell culture, due
to the composition of the receptor subunits included in these
receptors.
Despite the fact that the effect of Selank in the cell culture
investigated appears to be mediated by mechanisms unrelated
to a direct interaction with the GABAA receptor, the peptide
is able to change the affinity of the GABA to the GABAA
receptor (V’yunova et al., 2014). Previously, it was shown
that Selank is able to affect the specific binding of GABA to
GABAA receptors that may be caused by modulating properties
of the peptide, which appear to consist of a change of the
affinity of the endogenous ligands for the receptor under the
effects of Selank on the receptor (V’yunova et al., 2014).
We can assume that the reduction in the number of genes
that changed their expression from 14 (cell culture when
incubated with GABA) to one gene (incubation with Selank
and GABA) partially support the hypothesis of a possible effect
of the peptide through the regulation of GABAergic system
activity.
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FIGURE 3 | Gamma-aminobutyric acid signaling pathway.
It should be noted that, although olanzapine is an atypical
neuroleptic with pronounced affinity and activity for the
serotonin 5-HT2 receptor (Bymaster et al., 1996), the mechanism
of action of olanzapine may also be associated with the effect
on the GABAergic system. Thus, Skilbeck et al. have shown that
atypical antipsychotics, such as olanzapine, affect the density of
GABAA receptors in the prefrontal cortex (Skilbeck et al., 2007,
2008). Furthermore, the anxiolytic effect of olanzapine (Moore
et al., 1992; Inoue et al., 1996; Fu et al., 2000; Nemeroff, 2005)may
be associated with increasing concentrations of allopregnanolone
(Marx et al., 2000, 2003), which increases the frequency and
duration of opening of channels for chlorine ions and enhances
the inhibitory effect of GABA by binding to GABAA receptors
(Paul and Purdy, 1992; Twyman and MacDonald, 1992). Our
data confirm that olanzapine is able to affect the expression of the
GABAergic system genes, providing a pronounced effect on the
mRNA levels of genes studied in the culture of the neuroblastoma
IMR-32 cells. The presence of a pronounced positive correlation
between changes in gene expression under the effect of GABA
and olanzapine also provides support. It was demonstrated that
olanzapine has a very weak affinity for the GABAA receptor,
which is represented in various tissues of humans and rats
(Bymaster et al., 1996). It can be assumed that the features of
the subunit composition of GABAA receptors of this cell type
affects the receptor affinity to olanzapine. On the other hand,
the observed changes in the mRNA levels of the genes studied
after the incubation of IMR-32 cell culture with olanzapine
may be mediated by its effects on receptor systems that differ
from the GABAergic system. Although neuroblastoma cell line
IMR-32 predominantly express functional GABAA receptors, the
receptors of other systems (for example, nicotinic andmuscarinic
acetylcholine receptors) are present in the cell culture (Fraser and
Lee, 1995; Gopalakrishnan et al., 2011).
Moreover, the data obtained indicate that the number of genes
that changed their expression after the incubation with mixture
of Selank and olanzapine is higher than the number of genes
whosemRNA levels changed after the incubationwith olanzapine
alone. In addition, changes of transcript levels became more
pronounced, which indicates that Selank may enhance the effect
of olanzapine on expression of the genes studied. Unfortunately,
although we currently do not have a detailed explanation for this
phenomenon, we canmake the following supposition: olanzapine
binds to the GABAA receptor and changes its structure so that
Selank becomes capable of allosterically modulating the receptor
and thereby enhances the effect of olanzapine in the cell culture
studied.
The GSEA of the genes which mRNA levels changed
significantly in neuroblastoma cells IMR-32 after incubation with
the mixture of Selank and olanzapine showed that proteins
encoded by these genes play important roles in processes of
signal transduction in neurons, because biological processes,
revealed by Gene Ontology enrichment analysis, are involved
in neurotransmission. We also analyzed “gamma-aminobutyric
acid signaling pathway,” the most significant of the biological
processes identified, and built a scheme that visualized a
functional relations between entities of this biological process and
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where brain derived neurotrophic factor (BDNF) played central
role (Figure 3). It was shown that Selank may regulate expression
of Bdnf in rat hippocampus after intranasal administration
(Inozemtseva et al., 2008). Therefore, the observed changes in
expression of the genes studied in neuroblastoma cells IMR-
32 after incubation with the mixture of Selank and olanzapine
suggest that Selank may modulate the action of olanzapine by
affecting BDNF.
Thus, the data obtained indicate that Selank has no direct
effect on the expression of genes of the GABAergic system in
neuroblastoma IMR-32 cells. We can assume, that difference
between expression profiles after the incubation with GABA and
mixture of Selank and GABA partially confirms the hypothesis
that the peptide may affect the interaction of GABA with GABAA
receptors.
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